Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.50 |
| ▸ | MRGPRX1 | Q96LB2 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663236 | 0.82 | ALDH1A1 (0.44) | CA2CA1PTGES2THRB | |
| SCHEMBL19303542 | 0.81 | PSIP1 (0.51) | PSIP1MRGPRX1LMNAHPGDHSD17B10 | |
| SCHEMBL28021196 | 0.79 | PSIP1 (0.62) | PSIP1MRGPRX1LMNAHPGDHSD17B10 | |
| SCHEMBL30566205 | 0.76 | PSIP1 (0.59) | PSIP1LMNAHPGDHSD17B10KMT2A | |
| SCHEMBL6658979 | 0.76 | CA2 (0.67) | CA2CA1 | |
| SCHEMBL6221236 | 0.76 | PSIP1 (0.59) | PSIP1LMNAHPGDHSD17B10KMT2A | |
| SCHEMBL3631632 | 0.74 | KMT2A (0.40) | HPGDKMT2ATHRBMEN1 | |
| SCHEMBL1290833 | 0.74 | PSIP1 (0.61) | PSIP1LMNAHPGDHSD17B10PTGES2 | |
| SCHEMBL31047810 | 0.74 | PSIP1 (0.51) | PSIP1MRGPRX1LMNAHPGDHSD17B10 | |
| SCHEMBL6662068 | 0.73 | PSIP1 (0.47) | PSIP1MRGPRX1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244615-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | DDT, PFAS, DAO | PSIP1 1439/4885MRGPRX1 4229/4885LMNA 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.